8-K Report (10.18.13) Election Results



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
October 18, 2013

HEMISPHERX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)

Delaware
 
0‑27072
 
52-0845822
(state or other juris-
 
(Commission
 
(I.R.S. Employer
diction of incorporation)
 
File Number)
 
(Identification No.)

1617 JFK Boulevard, Suite 500, Philadelphia, PA
 
19103
(Address of principal executive offices)
 
(Zip Code)
 
 
 
Registrant's telephone number, including area code: (215) 988-0080
 
1617 JFK Boulevard, Suite 660, Philadelphia, PA 19103
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 5.07 Submission of Matters to a Vote of Security Holders

The Company’s Annual Meeting of Stockholders for 2013 was held on October 18, 2013. The requisite quorum for the meeting of 33.3% was present. At the meeting, stockholders voted as follows:

Election of Directors:

Nominees
For
Withheld
Broker Non-Votes
 
 
 
 
William A. Carter
18,140,207
3,077,710
69,564,045
Thomas K. Equels
18,774,055
2,443,862
69,564,045
William M. Mitchell
17,006,467
4,211,450
69,564,045
Iraj E. Kiani
16,787,204
4,430,713
69,564,045
Peter W. Rodino, III
19,633,622
1,584,295
69,564,045


Ratification of the appointment of McGladrey LLP as our independent accountants:

For: 87,101,794
Against: 2,538,111
Abstain: 1,142,057


Annual, non-binding advisory resolution, by stockholders on the elements of Executive Compensation:

For: 9,289,452
Against: 11,418,922
Abstain: 509,143
Broker Non-Votes: 69,564,045


For more information, please see the October 18, 2013 press released furnished as exhibit 99.1 to this report.


Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits:         Description
99.1
Press release dated October 18, 2013.


1



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
HEMISPHERX BIOPHARMA, INC.
 
 
 
 
October 18, 2013
 
By:
/s/ Charles T. Bernhardt
 
 
 
Charles T. Bernhardt
 
 
 
Chief Financial Officer


2